Cold chain (revision 10)
Old revision·00:15, 14 Jul 2024·CrossRefCleve
| Cold chain | |
|---|---|
| Scope | Manufacture, warehousing, freight, last mile, end use |
| Principal controlled variable | Temperature |
| Principal monitoring device | Electronic temperature data logger |
| Principal documented output | A continuous temperature record with custody points |
| Topic infobox · conventions | |
A cold chain is an unbroken sequence of temperature-controlled storage, handling and transport operations that maintains a temperature-sensitive product within its labelled storage conditions from the point of manufacture to the point of use. The term is used both for the physical arrangement — refrigerated rooms, insulated shippers, coolant, vehicles — and for the documentary system of records and custody transfers that demonstrates the arrangement worked.[1]
The concept originates in vaccine distribution, where it was developed from the 1970s onward as part of expanded immunisation programmes, and it retains much of that vocabulary. It has since been generalised to any product whose labelled storage conditions are narrower than ambient, including insulin and the GLP-1 receptor agonists, most of which are labelled for storage at 2–8 °C before first use.[2]
Two properties distinguish a cold chain from ordinary logistics. It is a chain in the strict sense that its integrity is set by its weakest link rather than by an average: an hour on an unshaded loading dock is not offset by a week of correct refrigeration. And its principal failure is invisible on inspection, because temperature-mediated degradation of a peptide or protein product generally produces no visible change. This combination is why monitoring instrumentation, rather than examination of the product, carries the evidentiary burden.[3]
Storage classes and their definitions
[edit]Labelled storage statements draw on compendial definitions rather than on plain language, and the definitions are narrower than everyday usage suggests. USP General Chapter <659> defines the terms used on United States labelling, and the European Pharmacopoeia and WHO guidance use closely comparable ranges.[4][1]
| !Term | Range | Notes |
|---|---|---|
| Freezer | −25 to −10 °C | Not the same as a domestic freezer, which may run colder |
| Cold | 2–8 °C | The range meant by "refrigerated" on a label |
| Cool | 8–15 °C | Seldom used on modern labelling |
| Controlled cold temperature | 2–8 °C, with permitted excursions between −20 and 25 °C | Excursions are bounded in duration and by mean kinetic temperature |
| Controlled room temperature | 20–25 °C, excursions 15–30 °C permitted, mean kinetic temperature not above 25 °C | The permitted excursion band is part of the definition |
| Warm | 30–40 °C | |
| Excessive heat | above 40 °C |
Two features of this table are consequential and routinely missed. Controlled room temperature is not a synonym for whatever temperature a room happens to be; it is a specification with a permitted excursion band and a mean kinetic temperature ceiling, and a warehouse that averages 27 °C does not satisfy it. And the definitions of controlled cold and controlled room temperature both build permitted excursions into the definition itself, so a brief departure from the nominal band is not automatically an excursion in the regulatory sense — a distinction developed at Temperature excursion.[4]
Storage statements for the compounds covered on this wiki cluster in two groups. Manufactured injectable GLP-1 receptor agonists are labelled for cold storage before first use, with an in-use period at higher temperature after first use. Lyophilised research peptides are commonly accompanied by a recommendation of frozen or cold storage for long-term holding and a statement that the dry material tolerates ambient transit, a combination whose physical basis is set out at Lyophilisation and whose evidential basis is generally absent.[5]
References
- ^ a b World Health Organization. "Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products." WHO Technical Report Series No. 961, Annex 9 (2011), with associated technical supplements.
- ^ Lloyd J, Cheyne J. "The origins of the vaccine cold chain and a glimpse of the future." Vaccine 35(17):2115–2120 (2017).
- ^ Kartoglu U, Milstien J. "Tools and approaches to ensure quality of vaccines throughout the cold chain." Expert Review of Vaccines 13(7):843–854 (2014).
- ^ a b United States Pharmacopeia, General Chapter <659>, "Packaging and Storage Requirements". USP–NF, current revision.
- ^ International Council for Harmonisation, Q1A(R2): Stability Testing of New Drug Substances and Products (2003).